# Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer

> **NCT00001493** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 42 (—)

## Conditions studied

- Breast Neoplasms
- Neoplasm Metastasis

## Interventions

- **GENETIC:** peripheral blood progenitor cells carrying MDR1

## Key facts

- **NCT ID:** NCT00001493
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-10
- **Primary completion:** —
- **Final completion:** 2000-06
- **Target enrollment:** 42 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001493, "Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00001493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*